Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Bank of New Hampshire

Bank of New Hampshire trimmed its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 1.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,125 shares of the company’s stock after selling 228 shares during the period. Bank of New Hampshire’s holdings in Henry Schein were worth $1,297,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in HSIC. GAMMA Investing LLC bought a new position in shares of Henry Schein in the fourth quarter worth $115,000. Linden Thomas Advisory Services LLC grew its stake in shares of Henry Schein by 10.0% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 8,345 shares of the company’s stock worth $632,000 after purchasing an additional 760 shares in the last quarter. Illinois Municipal Retirement Fund grew its stake in shares of Henry Schein by 16.5% in the fourth quarter. Illinois Municipal Retirement Fund now owns 95,324 shares of the company’s stock worth $7,217,000 after purchasing an additional 13,482 shares in the last quarter. Wedge Capital Management L L P NC boosted its stake in Henry Schein by 5.8% during the fourth quarter. Wedge Capital Management L L P NC now owns 471,419 shares of the company’s stock valued at $35,691,000 after buying an additional 26,010 shares in the last quarter. Finally, Lee Danner & Bass Inc. boosted its stake in Henry Schein by 7.1% during the fourth quarter. Lee Danner & Bass Inc. now owns 30,190 shares of the company’s stock valued at $2,286,000 after buying an additional 2,010 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the subject of several research reports. Evercore ISI raised their target price on Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. raised their target price on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Jefferies Financial Group raised their target price on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. SVB Leerink began coverage on Henry Schein in a report on Monday, February 26th. They set a “market perform” rating and a $78.00 target price for the company. Finally, Piper Sandler upped their target price on Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $81.09.

Henry Schein Trading Up 0.7 %

Shares of Henry Schein stock traded up $0.52 during trading on Friday, reaching $73.34. 249,247 shares of the company were exchanged, compared to its average volume of 1,073,478. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $82.63. The business has a 50-day moving average price of $74.23 and a 200-day moving average price of $72.43. The firm has a market capitalization of $9.42 billion, a price-to-earnings ratio of 23.12, a P/E/G ratio of 1.81 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The company had revenue of $3.02 billion for the quarter, compared to analyst estimates of $3 billion. During the same period last year, the firm earned $1.21 earnings per share. The firm’s revenue for the quarter was down 10.5% on a year-over-year basis. Sell-side analysts anticipate that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.